Edwards Lifesciences Corporation (NYSE:EW) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Edwards Lifesciences Corporation (NYSE:EW) have earned an average rating of “Moderate Buy” from the twenty-six analysts that are currently covering the stock, Marketbeat.com reports. Eight investment analysts have rated the stock with a hold recommendation, sixteen have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $97.0870.

Several analysts have issued reports on EW shares. Barclays restated an “overweight” rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Robert W. Baird lifted their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. BTIG Research boosted their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Mizuho set a $95.00 price target on Edwards Lifesciences and gave the company an “outperform” rating in a research report on Monday, April 13th. Finally, Citigroup raised their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th.

Edwards Lifesciences Price Performance

EW opened at $92.22 on Monday. The company has a market capitalization of $53.10 billion, a P/E ratio of 49.05, a PEG ratio of 2.31 and a beta of 0.86. The company has a 50-day moving average of $86.73 and a 200-day moving average of $83.85. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. Edwards Lifesciences has a 1-year low of $72.30 and a 1-year high of $96.29.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. The business had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities analysts expect that Edwards Lifesciences will post 3 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $91.70, for a total value of $56,762.30. Following the completion of the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at approximately $3,671,117.80. The trade was a 1.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the transaction, the senior vice president directly owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 45,577 shares of company stock worth $3,855,527 over the last 90 days. Insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Large investors have recently bought and sold shares of the business. MV Capital Management Inc. acquired a new stake in Edwards Lifesciences in the fourth quarter worth approximately $26,000. Hanson & Doremus Investment Management acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at $25,000. Kemnay Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth about $27,000. JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the third quarter worth about $25,000. Finally, Hilton Head Capital Partners LLC purchased a new position in shares of Edwards Lifesciences in the fourth quarter worth approximately $28,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.